Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 300 of 2529 entries
View as:

Effect of Fingolimod on Neurodegeneration

Phase: N/A Priority: Normal
NCT ID: NCT02575365 Org: User:
Start: 02/16/16 End: 01/27/17 Due: 01/27/18

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

Phase: N/A Priority: Normal
NCT ID: NCT04456023 Org: User:
Start: 01/31/22 End: 09/27/27 Due: 09/27/28

A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01647789 Org: User:
Start: 12/04/12 End: 02/03/16 Due: 02/03/17

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Phase: N/A Priority: Normal
NCT ID: NCT04720157 Org: User:
Start: 06/09/21 End: 02/11/26 Due: 02/11/27

Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02550106 Org: User:
Start: 04/22/15 End: 01/11/16 Due: 01/11/17

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01928459 Org: User:
Start: 10/31/13 End: 08/31/16 Due: 08/31/17

A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT05462873 Org: User:
Start: 04/04/23 End: 09/16/25 Due: 09/16/26

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT04895748 Org: User:
Start: 11/30/21 End: 09/26/25 Due: 09/26/26

Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa

Phase: N/A Priority: Normal
NCT ID: NCT06840392 Org: User:
Start: 03/20/25 End: 10/20/28 Due: 10/20/29

A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in Germany

Phase: N/A Priority: Normal
NCT ID: NCT06991608 Org: User:
Start: 06/11/24 End: 12/31/25 Due: 12/31/26

Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC

Phase: N/A Priority: Normal
NCT ID: NCT00709761 Org: User:
Start: 07/02/08 End: 01/03/18 Due: 01/03/19

Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)

Phase: N/A Priority: Normal
NCT ID: NCT01594281 Org: User:
Start: 12/11/12 End: 12/05/17 Due: 12/05/18

The 'Wearing Off' Effect of DMT

Phase: N/A Priority: Normal
NCT ID: NCT05627271 Org: User:
Start: 01/10/23 End: 04/20/23 Due: 04/20/24

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Phase: N/A Priority: Normal
NCT ID: NCT04722666 Org: User:
Start: 07/20/21 End: 09/26/23 Due: 09/26/24

Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy

Phase: N/A Priority: Normal
NCT ID: NCT01398592 Org: User:
Start: 06/30/11 End: 06/30/12 Due: 06/30/13

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT02299505 Org: User:
Start: 04/09/15 End: 03/06/20 Due: 03/06/21

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

Phase: N/A Priority: Normal
NCT ID: NCT06155500 Org: User:
Start: 04/16/24 End: 01/11/39 Due: 01/11/40

Ranibizumab "Treat and Extend" in Diabetic Macular Edma

Phase: N/A Priority: Normal
NCT ID: NCT01297569 Org: User:
Start: 01/31/11 End: 11/30/12 Due: 11/30/13

Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01374906 Org: User:
Start: 11/04/11 End: 12/21/16 Due: 12/21/17

Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR

Phase: N/A Priority: Normal
NCT ID: NCT06130540 Org: User:
Start: 03/27/24 End: 04/02/25 Due: 04/02/26

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Phase: N/A Priority: Normal
NCT ID: NCT05147220 Org: User:
Start: 12/16/21 End: 10/30/30 Due: 10/30/31

Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

Phase: N/A Priority: Normal
NCT ID: NCT06797518 Org: User:
Start: 02/24/25 End: 01/20/28 Due: 01/20/29

Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma

Phase: N/A Priority: Normal
NCT ID: NCT01912872 Org: User:
Start: 11/11/13 End: 01/08/16 Due: 01/08/17

Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.

Phase: N/A Priority: Normal
NCT ID: NCT01996319 Org: User:
Start: 04/30/14 End: 02/28/15 Due: 02/28/16

This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure

Phase: N/A Priority: Normal
NCT ID: NCT01035255 Org: User:
Start: 12/31/09 End: 05/31/14 Due: 05/31/15